NetworkNewsBreaks – CNS Pharmaceuticals Inc. (NA
Post# of 416
(Total Views: 51)
Posted On: 11/17/2025 3:53:49 PM
NetworkNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reports Q3 Results and Advances Lead Candidate TPI 287 Toward Phase 2 GBM Study
CNS Pharmaceuticals (NASDAQ: CNSP) reported third-quarter 2025 results and highlighted continued progress with TPI 287, its blood-brain barrier–permeable abeotaxane in development for glioblastoma and other CNS tumors. The Company noted Phase 1 data showing potential BBB penetration and tumor responses, including 3 complete and 9 partial responses among 23 evaluable patients treated with TPI 287 plus bevacizumab, and plans to engage the FDA early next year on a registration-focused Phase 2 trial design in recurrent GBM. For the quarter, CNS reported a net loss of $3.3 million, R&D expenses of $2.2 million and G&A expenses of $1.1 million, ending the period with $9.9 million in cash, which is expected to fund operations into the second half of 2026.
NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://nnw.fm/CNSP
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
CNS Pharmaceuticals (NASDAQ: CNSP) reported third-quarter 2025 results and highlighted continued progress with TPI 287, its blood-brain barrier–permeable abeotaxane in development for glioblastoma and other CNS tumors. The Company noted Phase 1 data showing potential BBB penetration and tumor responses, including 3 complete and 9 partial responses among 23 evaluable patients treated with TPI 287 plus bevacizumab, and plans to engage the FDA early next year on a registration-focused Phase 2 trial design in recurrent GBM. For the quarter, CNS reported a net loss of $3.3 million, R&D expenses of $2.2 million and G&A expenses of $1.1 million, ending the period with $9.9 million in cash, which is expected to fund operations into the second half of 2026.
NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://nnw.fm/CNSP
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
(0)
(0)